1. Yaman O, Tokatli Z, Akand M, Elhan AH, Anafarta K. Characteristics of sildenafil erections in healthy young men. Asian J Androl. 2005; 7:395–8.
Article
2. Yuncu G, Ozkurt S, Sinik Z, Kiter G. Hemoptysis developing soon after use of sildenafil: an observation on two cases. Asian J Androl. 2006; 8:757–8.
Article
3. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest. 2010; 137:1164–71.
Article
4. Chockalingam A, Gnanavelu G, Venkatesan S, Elangovan S, Jagannathan V, Subramaniam T, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol. 2005; 99:91–5.
Article
5. Pereira e Silva JL, Araujo Neto CA, Marchiori E. Pulmonary hemorrhage after the use of sildenafil. Heart Lung. 2012; 41:407–8.
Article
6. Dixit R, Jakhmola P, Sharma S, Arya M, Parmej AR. Recurrent haemoptysis following sildenafil administration. Indian J Chest Dis Allied Sci. 2009; 51:119–20.
7. Moore RA, Edwards JE, McQuay HJ. Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol. 2002; 2:6.
Article
8. Sidharta PN, van Giersbergen PL, Wolzt M, Dingemanse J. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects. Br J Clin Pharmacol. 2014; 78:1035–42.
Article
9. Nour SM, Nour HA, Mehta JB, Roy TM, Byrd RP Jr. Hemoptysis and respiratory failure following sildenafil use for pulmonary hypertension. Tenn Med. 2013; 106:34–5.